



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of European Medicines

Agency (EMA), Scientific Committee members and experts

Public declaration of interests

I, **David Coghill**

Organisation/Company: EUNETHYDIS and The University of Dundee

Country: United Kingdom

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment with a Company

No Interest Declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2010-(current)	Shire	Lisdexamfetamine	ADHD

2.3 Strategic Advisory Role

Period	Company	Products	Therapeutic Indication
01/2009-(current)	Shire	Lisdexamfetamine and Equasym XL (extended release methylphenidate)	ADHD
01/2004-07/2011	Lilly	Atomoxetine (strattera)	ADHD
01/2001-01/2010	Janssen Cilag	Concerta (extended release methylphenidate)	ADHD
09/2009-10/2010	Flynn Pharma	Medikinet XL (extended release methylphenidate)	ADHD
08/2009-08/2009	Pfizer	Advice about potential for new molecules in treatment of ADHD	
12/2010-12/2010	Shering-Plough	Advice about treatment for bipolar disorder in children and adolescents	

2.4 Current Financial Interests

Company	Financial Interest
Shire	honoraria for speaking at meeting
Lilly	honoraria for speaking at meeting
Janssen Cilag	honoraria for speaking at meeting

Medice	honoraria for speaking at meeting
--------	-----------------------------------

2.5 Patent

No Interest Declared

2.6 Principal Investigator

Period	Company	Products	Therapeutic Indication
01/2009-(current)	Shire	Lisdexamfetamine	ADHD

2.7 Investigator

Period	Company	Products	Therapeutic Indication
01/2011-(current)	Shire	Lisdexamfetamine	ADHD

2.8 Grant / Funding to Institution

Company	Subject Matter
Shire	Research funding (investigator initiated)

2.9 Family Member Interest

No Interest Declared

SECTION 3: CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result

of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the EMA website.

Full Name:	David Coghill
Date:	2012-07-02

For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template